CHMP Backs Baricitinib, Lifmior for Rheumatoid Arthritis CHMP Backs Baricitinib, Lifmior for Rheumatoid Arthritis
The EMA ' s CHMP recommended baricitinib for rheumatoid arthritis and Lifmior for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, and plaque psoriasis.International Approvals
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Rheumatology News Alert Source Type: news
More News: Arthritis | Dermatology | Psoriasis | Psoriatic Arthritis | Rheumatoid Arthritis | Rheumatology | Skin